{
  "id": "1d177fa865b2f353",
  "title": "Pembrolizumab - Based Regimen Approved for Platinum - Resistant Ovarian Cancer",
  "description": "20260220T181500Z",
  "content": "",
  "source": "clinicaladvisor.com",
  "source_url": "https://www.clinicaladvisor.com/news/pembrolizumab-based-regimen-approved-for-platinum-resistant-ovarian-cancer/",
  "published_at": "20260220T181500Z",
  "fetched_at": "2026-02-21T00:28:01.720640+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.clinicaladvisor.com/news/pembrolizumab-based-regimen-approved-for-platinum-resistant-ovarian-cancer/",
    "url_mobile": "",
    "title": "Pembrolizumab - Based Regimen Approved for Platinum - Resistant Ovarian Cancer",
    "seendate": "20260220T181500Z",
    "socialimage": "https://www.clinicaladvisor.com/wp-content/uploads/sites/11/2024/01/CA_1200x675.png",
    "domain": "clinicaladvisor.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}